• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

    5/15/25 11:05:50 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Altimmune, Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    02155H200

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Ameriprise Financial, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,428,430.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,443,932.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,443,932.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TAM UK International Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TAM UK Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Asset Management Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    TC Financing Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Asset Management Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    CUSIP No.
    02155H200


    1Names of Reporting Persons

    Threadneedle Investment Services Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,324,639.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    1,324,639.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,324,639.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.7 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Altimmune, Inc
    (b)Address of issuer's principal executive offices:

    910 Clopper Road, Suite 201S, Gaithersburg, Maryland 20878
    Item 2. 
    (a)Name of person filing:

    (a) Ameriprise Financial, Inc. ("AFI") (b) TAM UK International Holdings Limited ("TAMUKI") (c) Threadneedle Holdings Limited ("THL") (d) TAM UK Holdings Limited ("TUHL") (e) Threadneedle Asset Management Holdings Limited ("TAMHL") (f) TC Financing Ltd ("TCFL") (g) Threadneedle Asset Management Limited ("TAML") (h) Threadneedle Investment Services Limited ("TISL") Persons (a) through (h) are sometimes referred to herein as the "Ameriprise Entities".
    (b)Address or principal business office or, if none, residence:

    (a) 145 Ameriprise Financial Center, Minneapolis, MN 55474 (b) Cannon Place, 78 Cannon Street, London, EC4N 6AG (c) Cannon Place, 78 Cannon Street, London, EC4N 6AG (d) Cannon Place, 78 Cannon Street, London, EC4N 6AG (e) Cannon Place, 78 Cannon Street, London, EC4N 6AG (f) Cannon Place, 78 Cannon Street, London, EC4N 6AG (g) Cannon Place, 78 Cannon Street, London, EC4N 6AG (h) Cannon Place, 78 Cannon Street, London, EC4N 6AG
    (c)Citizenship:

    (a) Delaware (b) United Kingdom (c) United Kingdom (d) United Kingdom (e) United Kingdom (f) United Kingdom (g) United Kingdom (h) United Kingdom
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    02155H200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person. AFI, as the parent company of the other Ameriprise Entities, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons. Each of the Ameriprise Entities disclaims beneficial ownership of any shares reported on this Schedule.
    (b)Percent of class:

    The information required by Item 4(b) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c) is set forth in Rows (5)-(9) and (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    AFI: See Exhibit I
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ameriprise Financial, Inc.
     
    Signature:/s/ Michael G. Clarke
    Name/Title:Michael G. Clarke, Senior Vice President, North America Head of Operations & Investor Services
    Date:05/15/2025
     
    TAM UK International Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    TAM UK Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Asset Management Holdings Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    TC Financing Ltd
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Asset Management Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025
     
    Threadneedle Investment Services Limited
     
    Signature:/s/ Michael G. Clarke
    Name/Title:By: Columbia Management Investment Advisers, LLC, as Attorney in Fact, By: Michael G. Clarke, SVP, North America H.O. & Investor Services
    Date:05/15/2025

    Comments accompanying signature:   Contact Information Charles Chiesa VP Fund Treasurer Global Operations and Investor Services Telephone: 617-385-9593 Exhibit Index Exhibit I Identification and Classification of the Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company. Exhibit II Joint Filing Agreement Exhibit III Powers of Attorney
    Get the next $ALT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT

    DatePrice TargetRatingAnalyst
    1/28/2026$20.00Overweight
    Barclays
    7/10/2025$1.00Sell
    Goldman
    2/28/2025Mkt Perform
    William Blair
    1/8/2025$18.00Buy
    Stifel
    11/12/2024$26.00Buy
    UBS
    4/29/2024Buy → Neutral
    Guggenheim
    1/24/2024$13.00Neutral
    Goldman
    3/22/2023$20.00 → $6.00Buy → Neutral
    Goldman
    More analyst ratings

    $ALT
    SEC Filings

    View All

    SEC Form S-8 filed by Altimmune Inc.

    S-8 - Altimmune, Inc. (0001326190) (Filer)

    2/6/26 4:07:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Inc. filed SEC Form 8-K: Other Events

    8-K - Altimmune, Inc. (0001326190) (Filer)

    2/3/26 4:05:32 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Altimmune Inc.

    SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)

    1/30/26 1:25:54 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

    GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The gross proceeds to the Company were approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering a

    1/29/26 5:54:07 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

    GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune.

    1/27/26 9:25:00 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

    GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential f

    1/5/26 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pisano Wayne bought $20,410 worth of shares (5,000 units at $4.08), increasing direct ownership by 59% to 13,498 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/9/26 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sohn Catherine A. bought $2,118 worth of shares (500 units at $4.24), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    1/5/26 4:05:39 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jorkasky Diane bought $2,003 worth of shares (527 units at $3.80) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    12/29/25 4:10:05 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Roberts M Scot converted options into 17,050 shares, covered exercise/tax liability with 5,188 shares and was granted 5,567 shares, increasing direct ownership by 18% to 112,824 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    2/3/26 4:15:42 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garg Vipin K converted options into 26,775 shares, covered exercise/tax liability with 11,632 shares and was granted 6,926 shares, increasing direct ownership by 5% to 424,519 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    2/2/26 4:15:29 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Jordt Raymond M was granted 4,571 shares, increasing direct ownership by 7% to 70,107 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    2/2/26 4:10:06 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Altimmune with a new price target

    Barclays initiated coverage of Altimmune with a rating of Overweight and set a new price target of $20.00

    1/28/26 7:15:18 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Altimmune

    William Blair initiated coverage of Altimmune with a rating of Mkt Perform

    2/28/25 7:17:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/17/24 11:16:51 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    10/16/24 4:21:16 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Financials

    Live finance-specific insights

    View All

    Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

    Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis Conference call to be held today at 8:00 a.m. ET GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing thera

    12/19/25 6:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

    GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to

    10/30/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care